Clinical Trial Update: TUMORAPA 1: Efficacy of Rapamycin in Secondary Prevention of Skin Cancers in Kidney Transplant Recipients [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating rapamycin (sirolimus) for secondary prevention of skin cancers in kidney transplant recipients. The study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Skin Cancer

Drugs mentioned

• Rapamune (sirolimus)

Snippet

Sponsor: Hospices Civils de Lyon | Conditions: Skin Cancer, Kidney Transplantation | Phase 3 | Status: COMPLETED